Zoetis Inc. $ZTS Shares Sold by Cresset Asset Management LLC

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Cresset Asset Management LLC lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 22.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 19,670 shares of the company's stock after selling 5,809 shares during the quarter. Cresset Asset Management LLC's holdings in Zoetis were worth $3,239,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ZTS. Vanguard Group Inc. grew its holdings in Zoetis by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company's stock valued at $6,842,222,000 after buying an additional 189,287 shares in the last quarter. Polen Capital Management LLC boosted its holdings in shares of Zoetis by 17.6% in the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock worth $1,448,401,000 after purchasing an additional 1,313,653 shares during the period. Northern Trust Corp boosted its holdings in shares of Zoetis by 13.3% in the 4th quarter. Northern Trust Corp now owns 6,426,394 shares of the company's stock worth $1,047,052,000 after purchasing an additional 755,893 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Zoetis by 2.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company's stock worth $847,293,000 after purchasing an additional 109,791 shares during the period. Finally, Unisphere Establishment boosted its holdings in shares of Zoetis by 7.3% in the 4th quarter. Unisphere Establishment now owns 4,800,000 shares of the company's stock worth $782,064,000 after purchasing an additional 325,000 shares during the period. Institutional investors own 92.80% of the company's stock.

Insiders Place Their Bets

In related news, EVP Roxanne Lagano sold 652 shares of the company's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the transaction, the executive vice president owned 15,129 shares of the company's stock, valued at approximately $2,571,930. This represents a 4.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.18% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ZTS. UBS Group dropped their price objective on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Piper Sandler lifted their target price on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research report on Monday, August 11th. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and decreased their target price for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Finally, Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and decreased their target price for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat, Zoetis presently has an average rating of "Moderate Buy" and a consensus target price of $202.43.

Zoetis Stock Down 0.8%

NYSE:ZTS traded down $1.2650 during mid-day trading on Thursday, hitting $155.4950. 2,411,616 shares of the company's stock traded hands, compared to its average volume of 3,540,633. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The company has a fifty day moving average of $154.00 and a 200 day moving average of $158.75. The company has a market capitalization of $68.91 billion, a P/E ratio of 26.76, a P/E/G ratio of 2.52 and a beta of 0.88. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company's quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.